This section publishes research on the variety and impact of chromosomal aberrations on all types of human cancer. Manuscripts on animal models of tumors are also welcome. Case reports can only be considered if they provide a comprehensive review of the literature or describe an as yet-unreported finding in the corresponding malignancy. The exclusive use of molecular cytogenetic approaches (including array-CGH), or a combination of those with banding cytogenetics, standard molecular genetic or modern high-throughput approaches, or with proteomic or epigenetic studies, is welcome.
Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
Deletion of 13q14 [del(13q)] is the most common cytogenetic change (50%) in chronic lymphoblastic leukemia (CLL), and it is a good prognostic factor if it is detected as a sole aberration by FISH. However, it ...
Citation: Molecular Cytogenetics 2021 14:2